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process and identify any implications for manufacturers. Methods: Relevant county 
council and agency websites were used to gather insight into the new NT-rådet evalu-
ation process. A non-systematic literature review was conducted to identify infor-
mation illustrating potential implications of this new process. Results: NT-rådet 
selects in-patient drugs for centralised evaluation and specifies the degree to which 
treatment introduction will be centralised. For high priority treatments, Tandvårds-
och Läkemedelförmånsverket (TLV), will perform a health economic evaluation, upon 
which NT-rådet will base their recommendation, which will be accompanied by a 
monitoring protocol to ensure the organised introduction of treatments to all county 
councils. For low priority treatments, only a health economic evaluation and recom-
mendation will be issued. Any other treatments will go through decentralised reim-
bursement processes. NT-rådet plan to publish recommendations on approximately 
25 products or important indications per year. To date, NT-rådet has issued eight 
recommendations, including one joint recommendation for the use of six Hepatitis 
C therapies. This particular recommendation followed a first of its kind risk-sharing 
agreement between all 21 county councils and industry, which was a key product 
of this new process. ConClusions: The new assessment process has centralised 
the evaluation of some in-patient drugs, but not all. Most new treatments will still 
undergo the decentralised process. Due to its infancy, the impact of the NT-rådet 
process on the uptake of new expensive drugs remains to be confirmed.
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objeCtives: To understand the differences in time to launch between countries 
and the differences in time to reimbursement from launch Methods: We com-
pared time to launch as well as the time to reimbursement from launch of new 
molecular entities granted marketing authorization between 2009 and 2013 across 
18 developed countries. In addition, we conducted a sub-analysis comparing these 
measures for oncology and first-in-class medicines. A comprehensive analysis of the 
regulatory and market access landscapes was also assessed in order to understand 
the reasons behind any differences. Results: A large variation in time to launch of 
all new molecular entities (90 to 430 days) and time to reimbursement from launch 
was observed across studied countries (90 to 540 days). However, countries could be 
classified into three distinct groups: Countries with faster time to launch as well as 
faster time to reimbursement from launch - tended to have regulations mandating 
quick access, especially immediate coverage through public reimbursement after 
regulatory approval (e.g. Germany, Japan). Countries with faster time to launch, but 
slower time to reimbursement - had large private insurance markets but delayed 
public reimbursement negotiations (e.g. Canada). Countries with slower time to 
launch but fast reimbursement after launch - had almost exclusively public reim-
bursement but lengthy public reimbursement negotiations (e.g. France and Italy). 
Among the slower to launch countries, both first-in-class and oncology products 
achieved faster times to launch than the average across all new medicines. There 
was no difference observed in the fast launch countries. ConClusions: Time to 
launch and time to reimbursement from launch in a country is highly dependent 
on local market structure and market access regulations.
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objeCtives: Since 2013, Food and Drugs Administration (FDA) Breakthrough 
Therapy status has enabled expedited development and review of therapies where 
preliminary evidence suggests substantial clinical improvements for serious/life-
threatening conditions. However, there was a pre-existing FDA expedited pathway: 
Accelerated Approval enabling market entry of drugs for serious conditions based 
on a surrogate endpoint likely to predict clinical benefit with confirmatory tri-
als completed post-approval. This abstract aims to compare access of therapies 
under both pathways to determine in which distinct circumstances they are being 
used Methods: All FDA approvals from January 2013-March 2015 were screened 
for any approvals under Breakthrough Status and/or Accelerated Approval and 
the disease areas and supportive data packages were extracted. Results: Since 
November 2013, when the first therapy was approved under Breakthrough sta-
tus, 13 drugs have been FDA-approved under Accelerated Approval and 21 under 
Breakthrough Status including 8 supported by both expedited programs. For the 14 
approvals under Breakthrough Status alone, 11 (79%) were supported by Phase 3 data 
with the remaining 3 (21%) supported by Phase 2. Of the 6 drugs under Accelerated 
Approval alone, 2 (33%) were approved on Phase 3 data with the remaining 4 (66%) 
supported by Phase 2. Of the 7 approved under both programs, only 1 (14%) was 
supported by Phase 3 data, 4 (57%) by Phase 2 data and 2 (29%) by only Phase 1 
data. 86% (12/14) Breakthrough Status alone approvals were for non-oncology drugs 
versus just 16% (1/6) for Accelerated Approval alone and 0% (0/7) for under both pro-
grams. ConClusions: Whereas Accelerated Approval is typically used for oncology 
drugs, Breakthrough Status has been frequently applied to non-oncology medicines. 
Accelerated Approval also frequently enables expedited access without available 
supporting Phase 3 data, unlike Breakthrough Status. Products with supported by 
both programs have gained access supported by only Phase 1 data.
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evaluating, deciding and procuring new technologies. A mini-HTA sheet was tested 
during the interview and questions asked about the relevance and clarity of the 
questions. Results: The current processes of the uptake of technologies is rela-
tively similar in all studied hospitals. There are no standard, transparent evidence 
requirements, nor systems to assess and document the rationales for uptake. The 
clinicians report their needs in free format; the HTA-tools are not know nor used. 
After reducing the number of questions in the mini-HTA-sheet and making some 
changes to its content, order and terminology, the willingness to use increased. 
Information needed for budget impact analysis was considered of particular inter-
est. Procurement officials were strong proponents of systematic and transparent 
assessment. ConClusions: HTA tools need to be tailored to the hospitals. Instead 
of top-down requests for HTA, a low threshold tool is needed to document and 
justify the need of a new technology. This would pave the way for managers with 
financial responsibility to request more thorough assessments. This is the point 
where the new AdHopHTA tools could come in place.
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objeCtives: Telemedicine has been an innovation driver within e-health initiatives 
in health care in recent years. However, the uptake of such initiatives in Germany 
is low. Key question on that is if non-adequate reimbursement/funding might be 
the key reason for the slow introduction of e-health. Methods: We have reviewed 
German e-health initiatives and assessed the requirements for available reimburse-
ment pathways specifically for telemedicine initiatives in Germany and grouped 
them according to the application setting. Results: Overall there are currently 289 
e-health initiatives implemented in Germany in only few centers (mainly Berlin, Bad 
Oeynhausen, Munich, Hamburg). Telemedicine is being handled as medical devices 
in Germany within the market access pathway. The exact process depends if the 
device is an inpatient or outpatient product. In the inpatient setting relevant DRG 
and OPS codes are applicable; theoretically NUB and additional fee (Zusatzentgelt) 
could also be applied for. In the outpatient setting, the reimbursement of e-health 
devices is driven through the respective catalogue of aids and appliances whereas 
the actual physician service would need to be reimbursed through the EBM 
(Einheitlicher Bewertungsmassstab). Currently there is no specific EBM code avail-
able, and health politicians have missed a deadline in 2014 to create one. Besides the 
self-payment option as individual physicians services (IGeL) there is the opportunity 
through selective contracts, particularly Disease Management Programs (DMPs) or 
integrated care contracts. Most telemedicine projects are currently being covered 
and tested in the latter ones (e.g. telemonitoring CHF, video Parkinson therapy). An 
alternative new route could also be the experimental coverage by the joint federal 
committee. ConClusions: Currently the most relevant market access pathway 
for telemedicine initiatives in Germany is through selective contracts. Once health 
politicians put e-health as a priority the introduction of specific DRG and EBM 
codes could initiate fast adaption and more telemedine introductions in Germany.
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objeCtives: The British Isles comprise 4 countries, each with their own distinct 
Health Technology Assessment (HTA) body: National Institute of Health and Care 
Excellence (NICE) in England, National Centre for Pharmacoeconomics (NCPE) in 
Ireland, Scottish Medicines Consortium (SMC) in Scotland and All Wales Medicines 
Strategy Group (AWMSG) in Wales. Although all four bodies are obligate cost-utility 
HTA agencies, they do utilise distinct assessment processes. This research aims to 
compare the number and type of appraisals and recommendation rates between 
these bodies during 2014. Methods: All publically available NICE Single Technology 
Appraisal, SMC, NCPE and AWMSG HTA reports were identified in 2014 and the drug, 
indication and outcome extracted. Results: NCPE conducted the greatest number 
of appraisals (60) followed by the SMC (52), NICE (29) and the AWMSG (25). However, it 
should be noted that 68% of NCPE appraisals were through its rapid review pathway 
(not needing a full pharmaco-economic assessment). The highest rate of positive full 
recommendations was made by NICE (86%), followed by AWMSG (84%), SMC (79%), 
and the NCPE (39%). However, there was variation in what proportions of these 
recommendations were for a restricted sub-population: SMC (47%), AWMSG (29%), 
NICE (15%) and NCPE (5%). The proportion of oncology drugs appraised was highest 
by NICE (37%) followed by NCPE (37%), SMC (21%) and AWMSG (4%). ConClusions: 
The NCPE reviewed the greatest number of medicines but also had by far the highest 
rejection rates. Although NICE, AWMSG, and SMC had similar acceptance rates, the 
SMC displayed a greater propensity to restrict indications, and AWMSG (and to a 
lesser extent the SMC) reviewed a low number of oncology drugs, typically high cost 
agents that have greater difficulties in attaining positive reimbursement decisions. 
Thus it appears that in 2014 NICE appeared to be the most generous HTA body in 
awarding positive recommendations!
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objeCtives: The decision to fund an in-patient drug is currently made on a regional 
level by formulary committees in each of the 21 Swedish county councils. A pilot 
project for a centralised route of assessment for expensive, new in-patient treatments 
was replaced by a permanent body, Nya Terapier Rådet (NT-rådet), for centralised 
evaluation in January 2015. The objective of this research is to understand this new 
